The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

Agostina Nardone, Rachel Schiff, Carmine De Angelis et al.|British Journal of Cancer|2018

Cited by 65